Nearly 30 Potamkin Award winners will be gathered November 3-4 | ELN Message Board Posts


Elan Corporation, plc

  ELN website

ELN   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  26979 of 548898  at  9/29/2006 9:45:01 AM  by

phaider


 In response to msg 26921 by  
view thread
Strong Buy

Nearly 30 Potamkin Award winners will be gathered November 3-4

 

Can you imagine having all the nobel prized winners from the last 20 years in any particular field gathered together in 1 scientific convention to discuss the topic of choice?  Well, that is exactly what is occurring on November 3rd and 4th in Tubingen,Germany.

 

I noticed that the following:

 

Since the first Potamkin award in 1988, there have been 42 Potomkin Award winners.  Nearly 30 will be speaking on the state of Alzhiemer’s research and discovery.

  1. Robert Terry                          Awarded Potamkin 1988

Seminal observation that synapse loss—the decay of connections between nerve cells in the brain—is a central cause of dementia in the disease

 

  1. Dennis Selkoe                       Awarded Potamkin 1989

Constructed Amyloid Cascade Hypothesis which suggests that the amyloid burden in Alzheimer's disease is a cause of the dementia seen in Alzheimer's patients. 

BOD Elan

Founder of Athena Neurosciences which was acquired by Elan 1996

 

  1. Konrad Beyreuther               Awarded Potamkin 1990

Answered in part, what causes usually-normal amyloid proteins to accumulate abnormally into plaques.  Provided foundational insights about how the brain-clogging plaques develop

 

  1. Donald Price                          Awarded Potamkin 1992

Developed several of the first experimental animal models of Alzheimer’s disease.  Significant because of the simple fact that Alzheimer’s disease does not  exist in any other species other than in humans.

 

  1. Alison Goate                          Awarded Potamkin 1993

Findings show that certain specificmutations in a gene known as the amyloid precursor protein (APP) can cause severe, earlyAlzheimer’s disease.  APOE play a critical role in determining when beta Amyloid will aggreagate, where it aggregates and the form in which it aggregates.  APOE plays a role in soluble beta Amyloid clearance.  To date, APOE remains the only proven genetic risk for the most common form of Alzhiemer’s.  (late onset AD, with age of onset >60).  Late onset Alzheimer’s accounts for more than 99 percent of all cases.

 

  1. Blas Frangione                     Awarded Potamkin 1993

Findings show that certain specificmutations in a gene known as the amyloid precursor protein (APP) can cause severe, earlyAlzheimer’s disease

 

  1. Christine Van Boeckhoven Awarded Potamkin 1993

Findings show that certain specificmutations in a gene known as the amyloid precursor protein (APP) can cause severe, earlyAlzheimer’s disease

 

  1. John Hardy                            Awarded Potamkin 1993

Findings show that certain specific mutations in a gene known as the amyloid precursor protein (APP) can cause severe, early onset Alzheimer’s disease.

Senior investigator at the National Institutes of Health

 

  1. Allen Roses                           Awarded Potamkin 1994

Isolated the first major genetic risk factor for Alzheimer’s, a gene called apolipoprotein E4 (APOE4).When overexpressed, APOE4 heightens the risk for Alzheimer’s disease.  Opponent of targeting amyloid deposition to treat Alzheimer’s.

Senior Vice President of Pharmacogenetics for GlaxoSmithKline

Oversees $2 billion oral diabetes drug Avandia which is now undergoing studies for effectiveness on Alzheimer’s disease

 

  1. Gerard Schellenberg            Awarded Potamkin 1994

Investigated new genetic causes of dementia.  Specifically, APOE polymorphisms and the presenilin genes. Discovered the sequence of faulty genes to excess amyloid protein involved in Alzheimer’s.  Specifically, genetic mutations involving the presenilin 1 and 2 genes, mutations that produce increased levels of the amyloid protein.

 

  1. Steve Younkin                      Awarded Potamkin 1995

Findings show that increased beta Amyloid, produced by APP mutations, form the characteristic amyloid plaques of Alzheimer’s.  He demonstrated the importance of the amyloid precursor protein (APP) mutations in producing increased amounts of the plaque by APP and that the amyloid plaque was formed by increased amounts of these beta amyloid monomers.

 

  1. Khalid Iqbal                           Awarded Potamkin 1995

Definitively identified a mutated version of tau as thesource of the “tangles.”

 

  1. Yasuo Ihara                           Awarded Potamkin 1995

Definitively identified a mutated version of tau as thesource of the “tangles.”

 

  1. Rudolph Tanzi                       Awarded Potamkin 1996

Shows convincingly that the presenilin  genes are critical for the processing of the amyloid precursor protein and that mutations in these genes cause early onset, dominantly inherited Alzheimer's disease.  This discovery was also associated with increased amounts of the Abeta peptide, which aggregated to form the amyloid plaque. Leads to the study and development of beta secretase inhibitors and gamma secretase inhibitors. (LY450139, which Elan has a 50 percent option in, is a gamma secretase inhibitor).

 

  1. Peter St. George-Hyslop      Awarded Potamkin 1996

Shows convincingly that the presenilin  genes are critical for the processing of the amyloid precursor protein and that mutations in these genes cause early onset, dominantly inherited Alzheimer's disease.  This discovery was also associated with increased amounts of the Abeta peptide, which aggregated to form the amyloid plaque.  Leads to the study and development of beta seratease, gamma seratease, inhibitors.

Scientific Officer to Ellipsis, partner to Transition Theapuetics from whom Transition Therapeutics aquired their AZD-103 from. Scientific advisor to Elan. Worked to develop APP mouse and AN1792 vaccine.

 

  1. Sangram Sisodia                  Awarded Potamkin 1997

Why Abeta peptides accumulate in the genetic form of the disease

 

  1. Michel Goedert                      Awarded Potamkin 1998

Insights into tau malformations

 

  1. Virginia Lee                           Awarded Potamkin 1998

Recognized for contributions to the advancement of the understanding of the neurofibrillary "tangles," one of the hallmark lesions of brains.affected by Alzheimer's disease.  Vocal proponet of Tau and tangles.

Married to John Trojanowski

 

  1. John Trojanowski                 Awarded Potamkin 1998

Recognized for contributions to the advancement of the understanding of the neurofibrillary "tangles," one of the hallmark lesions of brains.affected by Alzheimer's disease.

Married to Virginia Lee

 

  1. Mike Hutton                           Awarded Potamkin 2000

Insights into tau malformations

 

  1. Dale Schenk                          Awarded Potamkin 2001

Groundbreaking leap forward in therapeutics: used a transgenic mouse model PDAPP to develop an immunization therapy for Alzheimer’s. Prevented further amyloid accumulation and, in fact, reversed existing plaque. Findings so important as to warrant a rare solo award.

Senior VP, Chief Scientific Officer Elan

 

  1. Christian Haass                    Awarded Potamkin 2002

Lifelong analysis of the biological chain reactions that create amyloid buildup in the brain may soon lead to drugs that can interrupt those chain reactions and prevent Alzheimer’s progression.

 

  1. Bart De Strooper                  Awarded Potamkin 2002

Presenilins affect APP processing through their effects on gamma-secretase

 

  1. Leon Thal                               Awarded Potamkin 2004
Serves as permanent advisor on the FDA anti-dementia assessment team.

Encouraged Elan/Wyeth to conduct the study and presented the data available to date. At a packed symposium sponsored by Elan, Participants, who received one or two injections of AN1792, showed a small but significant improvement in three memory and three executive function tests (Gilman et al., 2005).

 

  1. Roger Ntisch                         Awarded Potamkin 2004

Provided convincing evidence that a causal connection exists between the beta Amyloid and neurofibrillary tangles.  Developer of the Tg2576 transgenic mouse model which expressed both beta Amyloid and Tau pathologies. Produced groundbreaking evidence linking beta-amyloid deposits to the formation of plaque and fiber tangles in the brain, both of which are viewed as contributing to the development of Alzheimer's disease. Working with AN1792 vaccine, demonstrated success in generating antibodies to help the brain defend itself against beta-amyloids. The net result was a significant slowing of the pace at which Alzheimer's patients lose cognitive functions and their ability to handle daily living activities.

 

  1. John Morris                           Awarded Potamkin 2005

Identifyied the earliest biological and psychological changes associated with Alzheimer’s disease, laying important groundwork for intervening when treatment may have its greatest benefit.

 

  1. Karen Ashe                            Awarded Potamkin 2006

Findings show that a specific oligomeric form of amyloid beta (A-Star) impairs memory

 

  1. Bradley Hyman                      Awarded Potamkin 2006
  2. Karen Duff                             Awarded Potamkin 2006

widely known for her innovative work in developing transgenic mouse “models” of age-related human brain diseases

 

 

Many have contributed/supported Elan success in Alzheimer’s research. These are some of the greatest minds and highly recognized in this scientific field.  If you plot the different institutions each of these researchers comes from, you would easily recoginize that this has truly been one incredible global effort to end this terrible disease. 

 

I am excited about the likelihood of success with AAB-001.  There is a high degree of specificity of the antibodies in AAB-001 and no unwanted cross-reactions with normal brain cells.   I believe this suggests that the immunization against beta-amyloid will be safe and beneficial in the treatment of Alzheimer’s disease.  The disparate research seems to support a positive outcome.  I suspect that November 3, may be a day of fireworks for Elanites.

 

 

Best Regards,

 

Paul

 



     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 79  
   Views: 940 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
26993 Re: Nearly 30 Potamkin Award winners will be gathered November 3-4 montaratalk 0 9/29/2006 10:12:02 AM




Financial Market Data provided by
.
Loading...